Phyton Biotech has received Regulatory Approval from China’s NMPA for its plant cell fermentation-derived Paclitaxel Active Pharmaceutical Ingredient.
Phyton Biotech is pleased to announce approval from China’s regulatory body – National Medical Products Administration (NMPA) - for Phyton’s Drug Master File for paclitaxel active pharmaceutical ingredient produced via plant cell fermentation (PCF®).
Phyton Biotech Announces the Successful Establishment of Plant Cell Lines to Source Key Building Block for Treatment of Rare Dermatologic Conditions
Phyton Biotech’s Plant Cell Fermentation (PCF) technology has been successfully used to develop high-yielding plant cell lines of the source of cyclopamine, a key raw material for PellePharm’s patedigib topical gel.
Phyton Biotech COVID-19 Update
Phyton Biotech is committed to the health and safety of our employees first, and minimizing any interruptions so we can reliably supply our Active Pharmaceutical Ingredients.
Phyton Biotech’s Vice-President, Sales & Marketing Interviewed by SpeakPharma
Phyton Biotech’s Vice-President, Sales & Marketing, Jackie Labbe was delighted to speak with SpeakPharma recently about Phyton Biotech.
Phyton Biotech® Launches New Video on its Specialty Fermentation Solutions
Watch the video now to learn more about Plant Cell Fermentation Technology®
Phyton Biotech Receives Patent for the Production of Ingenol-3-angelate, Using Plant Cell Fermentation (PCF®)
AqVida and Phyton Biotech Receive Approval from European Directorate of Quality Medicines.